XTNT vs. GLUE

Last updated Jun 4, 2026

XTNT (Xtant Medical Holdings, Inc.) and GLUE (Monte Rosa Therapeutics, Inc.) are both stocks. Both are in the Healthcare sector — XTNT in Medical Devices, GLUE in Biotechnology. Over the past 3 years, XTNT returned -11.11%/yr vs 32.51%/yr for GLUE. At a 0.13 correlation, their price movements are largely independent.

Performance

XTNT vs. GLUE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Xtant Medical Holdings, Inc. (XTNT) and Monte Rosa Therapeutics, Inc. (GLUE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, XTNT achieves a -41.31% return, which is significantly lower than GLUE's 12.18% return.

XTNT

• 1D: -1.05%
• 1M: -17.84%
• YTD: -41.31%
• 6M: -23.03%
• 1Y: -31.89%
• 3Y*: -11.11%
• 5Y*: -22.82%
• 10Y*: -33.15%

GLUE

• 1D: -0.85%
• 1M: -10.12%
• YTD: 12.18%
• 6M: 4.33%
• 1Y: 279.09%
• 3Y*: 32.51%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

XTNT vs. GLUE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
XTNT Xtant Medical Holdings, Inc.	-41.31%	76.98%	-60.80%	71.21%	17.86%	-66.86%
GLUE Monte Rosa Therapeutics, Inc.	12.18%	125.94%	22.83%	-25.76%	-62.73%	-3.59%

Correlation

The correlation between XTNT and GLUE is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.20
Correlation (3Y) Calculated over the trailing 3-year period	0.13
Correlation (All Time) Calculated using the full available price history since Jun 25, 2021	0.13

Fundamentals

EPS XTNT : $0.09 GLUE : -$2.26
PS Ratio XTNT : 0.34 GLUE : 23.56
Total Revenue (TTM) XTNT : $133.93M GLUE : $42.95M
Gross Profit (TTM) XTNT : $84.27M GLUE : $34.56M
EBITDA (TTM) XTNT : $22.15M GLUE : -$139.25M

Return for Risk

XTNT vs. GLUE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XTNT

XTNT Risk / Return Rank: 19
XTNT Sharpe Ratio Rank: 18
XTNT Sortino Ratio Rank: 19
XTNT Omega Ratio Rank: 21
XTNT Calmar Ratio Rank: 18
XTNT Martin Ratio Rank: 17

GLUE

GLUE Risk / Return Rank: 94
GLUE Sharpe Ratio Rank: 94
GLUE Sortino Ratio Rank: 95
GLUE Omega Ratio Rank: 92
GLUE Calmar Ratio Rank: 94
GLUE Martin Ratio Rank: 92

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XTNT vs. GLUE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Xtant Medical Holdings, Inc. (XTNT) and Monte Rosa Therapeutics, Inc. (GLUE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	XTNT	GLUE	Difference
Sharpe ratio: Return per unit of total volatility	-0.53	3.04	-3.57
Sortino ratio: Return per unit of downside risk	-0.54	4.23	-4.77
Omega ratio: Gain probability vs. loss probability	0.94	1.48	-0.54
Calmar ratio: Return relative to maximum drawdown	-0.63	6.72	-7.35
Martin ratio: Return relative to average drawdown	-1.12	14.78	-15.90
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

XTNT vs. GLUE - Sharpe Ratio Comparison

The current XTNT Sharpe Ratio is -0.53, which is lower than the GLUE Sharpe Ratio of 3.04. The chart below compares the historical Sharpe Ratios of XTNT and GLUE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	XTNT	GLUE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.53	3.04	-3.57
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.31	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.29	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.31	-0.04	-0.27

Drawdowns

XTNT vs. GLUE - Drawdown Comparison

The maximum XTNT drawdown since its inception was -99.17%, which is greater than GLUE's maximum drawdown of -94.08%. Use the drawdown chart below to compare losses from any high point for XTNT and GLUE.

Drawdown Indicators

	XTNT	GLUE	Difference
Max Drawdown Largest peak-to-trough decline	-99.17%	-94.08%	-5.09%
Max Drawdown (1Y) Largest decline over 1 year	-51.04%	-41.84%	-9.20%
Max Drawdown (3Y) Largest decline over 3 years	-74.78%	-67.19%	-7.59%
Max Drawdown (5Y) Largest decline over 5 years	-82.48%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-98.68%	—	—
Current Drawdown Current decline from peak	-98.91%	-58.33%	-40.58%
Average Drawdown Average peak-to-trough decline	-88.78%	-74.61%	-14.17%
Ulcer Index Depth and duration of drawdowns from previous peaks	28.46%	18.99%	+9.47%

Volatility

XTNT vs. GLUE - Volatility Comparison

The current volatility for Xtant Medical Holdings, Inc. (XTNT) is 13.15%, while Monte Rosa Therapeutics, Inc. (GLUE) has a volatility of 16.50%. This indicates that XTNT experiences smaller price fluctuations and is considered to be less risky than GLUE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	XTNT	GLUE	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.15%	16.50%	-3.35%
Volatility (6M) Calculated over the trailing 6-month period	37.62%	57.29%	-19.67%
Volatility (1Y) Calculated over the trailing 1-year period	59.99%	92.63%	-32.64%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	73.83%	101.31%	-27.48%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	113.46%	101.31%	+12.15%

Dividends

XTNT vs. GLUE - Dividend Comparison

Neither XTNT nor GLUE has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both XTNT and GLUE in my portfolio?

XTNT and GLUE have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, XTNT or GLUE?

GLUE has higher volatility (16.50%) compared to XTNT (13.15%). In terms of maximum drawdown, XTNT dropped -99.17% vs GLUE's -94.08%.

Which has better risk-adjusted returns?

GLUE currently has the higher Sharpe Ratio (3.04 vs -0.53), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.